{
    "clinical_study": {
        "@rank": "8284", 
        "acronym": "BIOSOLVE-II", 
        "arm_group": {
            "arm_group_label": "Drug Eluting Absorbable Metal Scaffold", 
            "arm_group_type": "Experimental", 
            "description": "DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold"
        }, 
        "brief_summary": {
            "textblock": "BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of\n      this study is to assess the safety and clinical performance of the drug eluting absorbable\n      metal scaffold (DREAMS 2nd Generation)."
        }, 
        "brief_title": "First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Coronary Artery Stenosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Coronary Stenosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is > 18 years and < 80 years of age\n\n          -  Written subject informed consent available prior to PCI\n\n          -  Subjects with stable or unstable angina pectoris or documented silent ischemia\n\n          -  Subject eligible for PCI\n\n          -  Subject acceptable candidate for coronary artery bypass surgery\n\n          -  Subjects with a maximum of two single lesions in two separate coronary arteries which\n             have to be de novo lesions.\n\n          -  Reference vessel diameter between 2.2-3.8 mm by visual estimation\n\n          -  Target lesion length \u2264 21 mm by visual estimation\n\n          -  Target lesion stenosis by visual estimation, assisted by QCA / IVUS:  > 50% - < 100%\n\n          -  Eligible for Dual Anti Platelet Therapy (DAPT)\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding females or females who intend to become pregnant during\n             the time of the study\n\n          -  Evidence of myocardial infarction within 72 hours prior to index procedure\n\n          -  Subjects with a \u22652 fold CK level or in absence of CK a \u22653 fold CKMB level above the\n             upper range limit within 24 hours prior to the procedure\n\n          -  Unprotected left main coronary artery disease\n\n          -  Three-vessel coronary artery disease at time of procedure\n\n          -  Thrombus in target vessel\n\n          -  Subject is currently participating in another study with an investigational device or\n             an investigational drug and has not reached the primary endpoint yet\n\n          -  Planned interventional treatment of any non-target vessel within 30 days\n             post-procedure\n\n          -  Subjects on dialysis\n\n          -  Planned intervention of the target vessel within 6-month after the index procedure\n\n          -  Ostial target lesion (within 5.0 mm of vessel origin)\n\n          -  Target lesion involves a side branch >2.0 mm in diameter\n\n          -  Documented left ventricular ejection fraction (LVEF) \u2264 30%\n\n          -  Heavily calcified lesion\n\n          -  Target lesion is located in or supplied by an arterial or venous bypass graft\n\n          -  The target lesion requires treatment with a device other than the pre-dilatation\n             balloon prior to scaffold placement (including but not limited to, rotational\n             atherectomy, cutting balloon etc.)\n\n          -  Known allergies to: Acetylsalicylic Acid (ASA), Heparin, Contrast medium, Sirolimus,\n             or similar drugs; or the scaffold material\n\n          -  Impaired renal function (serum creatinine > 2.5 mg/dl or 221 mmol/l, determined\n             within 72 hours prior to intervention)\n\n          -  Subject is receiving oral or intravenous immuno-suppressive therapy (e.g., inhaled\n             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune\n             disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not\n             including diabetes mellitus)\n\n          -  Proximal or distal to the target lesion located stenosis that might require future\n             revascularization or impede run off detected during diagnostic angiography\n\n          -  Life expectancy less than 1 year\n\n          -  Planned surgery or dental surgical procedure within 6 months after index procedure\n\n          -  In the investigators opinion subjects will not be able to comply with the follow-up\n             requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "121", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960504", 
            "org_study_id": "C1209"
        }, 
        "intervention": {
            "arm_group_label": "Drug Eluting Absorbable Metal Scaffold", 
            "intervention_name": "Percutaneous Coronary Intervention (DREAMS) stenting", 
            "intervention_type": "Device", 
            "other_name": "DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DREAMS", 
            "Drug Eluting Absorbable Metal Scaffold", 
            "Scaffold", 
            "Coronary Artery Disease", 
            "Myocardial Ischemia", 
            "Atherosclerosis"
        ], 
        "lastchanged_date": "October 23, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "William Wijns, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }, 
                    "name": "OLV-Ziekenhuis Aalst"
                }, 
                "investigator": {
                    "last_name": "William Wijns, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexandre Abizaid"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "04012-909"
                    }, 
                    "name": "Instituto Dante Pazzanese de Cardiologia"
                }, 
                "investigator": {
                    "last_name": "Alexandre Abizaid, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pedro A. Lemos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "05403-000"
                    }, 
                    "name": "Instituto do Cora\u00e7\u00e3o - HCFMUSP"
                }, 
                "investigator": {
                    "last_name": "Pedro A. Lemos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Evald H\u00f8j Christiansen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "zip": "8200"
                    }, 
                    "name": "Aarhus University Hospital"
                }, 
                "investigator": {
                    "last_name": "Evald H\u00f8j Christiansen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Franz-Josef Neumann, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Krozingen", 
                        "country": "Germany", 
                        "zip": "79189"
                    }, 
                    "name": "Universit\u00e4ts-Herzzentrum Freiburg Bad Krozingen"
                }, 
                "investigator": {
                    "last_name": "Franz-Josef Neumann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ralph T\u00f6lg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Segeberg", 
                        "country": "Germany", 
                        "zip": "D-23795"
                    }, 
                    "name": "Segeberg Kliniken GmbH, Herzzentrum"
                }, 
                "investigator": {
                    "last_name": "Ralph T\u00f6lg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Haude, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany", 
                        "zip": "41464"
                    }, 
                    "name": "St\u00e4dtische Kliniken Neuss - Lukaskrankenhaus"
                }, 
                "investigator": {
                    "last_name": "Michael Haude, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Clemens von Birgelen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "zip": "7513ER"
                    }, 
                    "name": "Thoraxcentrum Twente"
                }, 
                "investigator": {
                    "last_name": "Clemens von Birgelen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lim Soo Teik, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Mistri Wing", 
                        "country": "Singapore", 
                        "zip": "168752"
                    }, 
                    "name": "National Heart Centre Singapore"
                }, 
                "investigator": {
                    "last_name": "Lim Soo Teik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nieves Gonzalo Lopez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Clinico San Carlos"
                }, 
                "investigator": {
                    "last_name": "Nieves Gonzalo Lopez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christoph Kaiser, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "University Hospital Basel"
                }, 
                "investigator": {
                    "last_name": "Christoph Kaiser, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eric Eeckhout, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1011"
                    }, 
                    "name": "CHUV - Centre Hospitalier Universitaire Vaudois"
                }, 
                "investigator": {
                    "last_name": "Eric Eeckhout, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Brazil", 
                "Denmark", 
                "Germany", 
                "Netherlands", 
                "Singapore", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II", 
        "overall_contact": {
            "email": "banu.eyueboglu.seitz@biotronik.com", 
            "last_name": "Banu Eyueboglu Seitz, PhD", 
            "phone": "+41 44 864 5872"
        }, 
        "overall_contact_backup": {
            "email": "tamara.koch@biotronik.com", 
            "last_name": "Tamara Koch", 
            "phone": "+41 44 864 58 77"
        }, 
        "overall_official": {
            "affiliation": "St\u00e4dtische Kliniken Neuss", 
            "last_name": "Michael Haude, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Switzerland: Swissmedic", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Denmark: Danish Health and Medicines Authority", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Brazil: National Health Surveillance Agency", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "In segment Late Lumen Loss", 
            "safety_issue": "Yes", 
            "time_frame": "6 months post index procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960504"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Target Lesion Failure (TLF), defined as composite of cardiac death, target vessel Q-wave or non-Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularisation (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6, 12, 24 and 36 months"
            }, 
            {
                "measure": "Scaffold thrombosis rate", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6, 12, 24 and 36 months"
            }, 
            {
                "measure": "In-scaffold and in-segment Binary Restenosis Rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "In-scaffold and in-segment Percent Diameter Stenosis", 
                "safety_issue": "Yes", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Late Lumen Loss in segment", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Late Lumen Loss in scaffold", 
                "safety_issue": "Yes", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "description": "Procedure Success defined as achievement of a final diameter stenosis of <30% by QCA, using any percutaneous method, without the occurrence of death, Q-wave or WHO defined non-Q-wave, or repeat revascularization of the target lesion during the hospital stay.", 
                "measure": "Procedure success", 
                "safety_issue": "Yes", 
                "time_frame": "During the hospital stay to a maximum of the first seven days post index procedure"
            }, 
            {
                "description": "Device Success is defined as a final residual diameter stenosis of <30% by QCA, using the assigned device only\nsuccessful delivery of the scaffold to the target lesion site in the coronary artery\nappropriate scaffold deployment\nsuccessful removal of the device\nsafe removal of the device in case of deployment failure", 
                "measure": "Device success", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0"
            }
        ], 
        "source": "Biotronik AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biotronik AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}